While it typically promotes tumor progression through immune evasion – evidenced by elevated PDCD1LG2 expression in GC tissues correlating with immunosuppressive microenvironments and chemoresistance[25] – emerging preclinical studies reveal paradoxical immunostimulatory effects. The gene discussed is PDCD1LG2; the disease is neoplasm.